Mirum Pharmaceuticals develops therapies for rare liver diseases, including cholestatic conditions like Alagille syndrome and PFIC. Its flagship drug, Livmarli, treats cholestatic pruritus in patients aged three months and older. Pediatric and adult patients with limited treatment options benefit most, gaining improved bile flow and reduced itching.
Get alerts when this topic surges in newsletters. Free to start.
Sign up freeExplore more trends:Trending Topics ·AI Trends ·Business Trends ·Finance Trends ·Technology Trends